keyword
MENU ▼
Read by QxMD icon Read
search

Chronic urticaria

keyword
https://www.readbyqxmd.com/read/28441994/a-30-year-old-woman-with-chronic-hives-intermittent-fevers-and-joint-pain
#1
Kevin A Cook, Megan T Lynch, Peter J Weis, Andrew A White
Chronic urticaria with concomitant systemic symptoms may be seen in several rheumatologic and autoinflammatory conditions. Although most of these conditions tend to improve with corticosteroids, symptoms often recur with dose tapering. The appearance of the rash in addition to the symptom pattern and laboratory data must be considered to differentiate potential causes. We presented a unique case of chronic urticaria with fevers and arthralgias. A diagnosis was made, and the patient had rapid improvement with targeted therapy...
May 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28435464/clinical-efficacy-of-omalizumab-in-chronic-spontaneous-urticaria-is-associated-with-a-reduction-of-fc%C3%AE%C2%B5ri-positive-cells-in-the-skin
#2
Martin Metz, Petra Staubach, Andrea Bauer, Randolf Brehler, Janine Gericke, Michael Kangas, Joanna Ashton-Chess, Philip Jarvis, Panayiotis Georgiou, Janice Canvin, Rainer Hillenbrand, Veit J Erpenbeck, Marcus Maurer
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI(+)) and IgE-positive (IgE(+)) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. Study design. In a double-blind study, CSU patients aged 18‑75 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks...
2017: Theranostics
https://www.readbyqxmd.com/read/28429304/new-perspectives-on-the-diagnosis-of-allergy-to-anisakis-spp
#3
REVIEW
Ignacio Moneo, Noelia Carballeda-Sangiao, Miguel González-Muñoz
PURPOSE OF REVIEW: To compare the prevalence of sensitization in different countries based on specific IgE values and to evaluate the use of isolated native or recombinant allergens for diagnosis. RECENT FINDINGS: Isolated allergens help in the diagnosis of truly sensitized patients avoiding false positives due to cross-reactions. Their use is therefore highly recommended, especially when used as a combination of several relevant allergens. The use of purified allergens allows an accurate diagnosis and this has led to three important findings: (1) in addition to the digestive route of sensitization, occupational and non-digestive exposure seems to be clinically relevant...
May 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28428670/thyroid-autoimmunity-in-patients-with-chronic-urticaria
#4
Emina Kasumagic-Halilovic, Nermina Beslic, Nermina Ovcina-Kurtovic
INTRODUCTION: chronic urticaria (CU) is a skin disorder characterized by transient, pruritic wheals persisting for longer than 6 weeks. The etiopathogenesis of the disease is still unclear, but there is evidence that autoimmunity and endocrine dysfunction may be involved. AIM: the aim of this study was to determine whether chronic urticaria is statistically associated with thyroid autoimmunity. PATIENTS AND METHODS: in a prospective case-control study, we compared the frequency of thyroid auto-antibodies (thyroglobulin antibody, anti-Tg and thyroid peroxidase antibody, anti-TPO) in 70 patients with chronic urticaria and in 70 healthy volunteers...
February 2017: Medical Archives
https://www.readbyqxmd.com/read/28425596/histamine-intolerance-in-chronic-urticaria
#5
R Jarisch
No abstract text is available yet for this article.
April 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28407332/transcriptome-analysis-of-severely-active-chronic-spontaneous-urticaria-shows-an-overall-immunological-skin-involvement
#6
A Giménez-Arnau, L Curto-Barredo, L Nonell, E Puigdecanet, J Yelamos, R Gimeno, S Rüberg, L Santamaria-Babi, R M Pujol
BACKGROUND: The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the disease and its response to the available effective drugs. Genotype expression and its further correlation with CSU phenotypes are still unknown. We describe the cutaneous transcriptome of patients suffering a severely active CSU refractory to antihistamine treatment. METHODS: Through the bioinformatic analysis of the whole Human Genome with Oligo Microarrays and Quantitative real-time polymerase chain reaction (qPCR), relevant genes expressed in non-lesional [NLS-CSU] and lesional skin [LS-CSU]) and peripheral blood were identified in 20 patients suffering from severely active CSU and 10 healthy controls (HCs) RESULTS: From 39 genes differentially expressed in NLS-CSU when compared with HCs, 31 (79...
April 13, 2017: Allergy
https://www.readbyqxmd.com/read/28407273/comorbidity-of-chronic-spontaneous-urticaria-and-autoimmune-thyroid-diseases-a-systematic-review
#7
REVIEW
Pavel Kolkhir, Martin Metz, Sabine Altrichter, Marcus Maurer
Chronic spontaneous urticaria (CSU) patients are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG anti-thyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%. Levels of IgG against thyroid peroxidase (TPO) are more often elevated in CSU than those of other IgG anti-thyroid AAbs (strong evidence)...
April 13, 2017: Allergy
https://www.readbyqxmd.com/read/28405547/autologous-serum-and-plasma-skin-tests-in-chronic-spontaneous-urticaria-a-reappraisal
#8
Muthu Sendhil Kumaran, Sonia Mangal, Tarun Narang, Davinder Parsad
AIM: The objective of this study was to assess autologous serum skin test (ASST) vs autologous plasma skin test (APST) response in chronic spontaneous urticaria (CSU) patients and study the significance of intensity of positive responses in relation to clinicoepidemiological parameters. MATERIALS AND METHODS: One hundred CSU patients and 100 age and sex-matched controls were recruited. The demographic and clinical features were recorded in all patients and routine investigations were performed...
March 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28398413/imatinib-mesylate-induced-lichenoid-drug-eruption
#9
Erin H Penn, Hye Jin Chung, Matthew Keller
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28392912/erratum-to-looking-forward-to-new-targeted-treatments-for-chronic-spontaneous-urticaria
#10
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan
[This corrects the article DOI: 10.1186/s13601-016-0139-2.].
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28390587/clinical-features-of-adolescents-with-chronic-idiopathic-or-spontaneous-urticaria-review-of-omalizumab-clinical-trials
#11
Stanley Goldstein, Susan Gabriel, Farid Kianifard, Benjamin Ortiz, David P Skoner
BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups...
April 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28380487/effectiveness-of-autologous-whole-blood-injections-in-patients-with-refractory-chronic-spontaneous-urticaria
#12
Nikolaos Aggelis Kitsioulis, Paraskevi Xepapadaki, Aggeliki-Victoria Roussaki-Schulze, Nikolaos Papadopoulos, Efterpi Zafiriou
BACKGROUND: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluate changes in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q2oL) score, and also the association of serologic markers with disease severity measures after AWBI...
April 6, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28374082/the-leukotriene-receptor-antagonist-montelukast-and-its-possible-role-in-the-cardiovascular-field
#13
REVIEW
Malvina Hoxha, G Enrico Rovati, Aurora Bueno Cavanillas
BACKGROUND: Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are pro-inflammatory mediators of the 5-lipooxygenase (5-LO) pathway, that play an important role in bronchoconstriction, but can also enhance endothelial cell permeability and myocardial contractility, and are involved in many other inflammatory conditions. In the late 1990s, leukotriene receptor antagonists (LTRAs) were introduced in therapy for asthma and later on, approved for the relief of the symptoms of allergic rhinitis, chronic obstructive pulmonary disease, and urticaria...
April 4, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28366912/low-dose-rituximab-as-an-adjuvant-therapy-in-pemphigus
#14
Jaya Gupta, Ranjan C Raval, Arti N Shah, Rekha B Solanki, Dhara D Patel, Kaksha B Shah, Ami D Badheka, Keyur B Shah, Neetish K Aggarwal, Vaaruni Ravishankar
BACKGROUND: Pemphigus is a chronic autoimmune blistering disease where systemic steroids and immunosuppressants are the mainstay of therapy, but long-term treatment with these agents is associated with many side effects. Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids. AIM: To study the clinical efficacy and safety of low-dose rituximab as an adjuvant therapy in pemphigus. METHODS: Fifty patients with extensive pemphigus were selected, who either had recalcitrant pemphigus, were steroid dependent, had relapsed after pulse therapy, had anti-desmoglein levels >20, had contraindications to conventional treatment or wanted to avoid conventional treatment and its side effects...
March 29, 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28366479/biologic-therapy-in-the-treatment-of-chronic-skin-disorders
#15
REVIEW
James M Fernandez, Anthony P Fernandez, David M Lang
Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366435/efficacy-and-safety-of-omalizumab-in-japanese-and-korean-patients-with-refractory-chronic-spontaneous-urticaria
#16
Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami, Jooyoung Roh, Jae-Hyun Lee, Yuko Chinuki, Sang Woong Youn, Soo-Keol Lee, Naoko Inomata, Jeong-Hee Choi, Atsushi Fukunaga, Junyi Wang, Soichiro Matsushima, Steve Greenberg, Sam Khalil
BACKGROUND: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU...
March 21, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28351163/crp-relevance-in-clinical-assessment-of-chronic-spontaneous-urticaria-tunisian-patients
#17
Amal Maouia, Monia Youssef, Nadia Leban, Ahmed Noureddine Helal, Asma Kassab
BACKGROUND: Chronic spontaneous urticaria (CSU) is a common dermatological condition defined by the sudden occurrence of daily wheals and pruritus for at least 6 weeks. Multifactorial origin is suggested such as Oxidative stress. This latter may play a double role as a trigger and remnant agent. OBJECTIVES: The first aim of this study is to investigate antioxidant status, inflammatory proteins, hematologic counts and clinical assessment in CSU patients. The second aim is to evaluate the effect of a first-line treatment: Desloratadine 5mg/day on these different parameters...
March 28, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28332366/soluble-cd93-in-serum-as-a-marker-of-allergic-inflammation
#18
Hye Jung Park, Heejae Han, Sang Chul Lee, Young Woong Son, Da Woon Sim, Kyung Hee Park, Yoon Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee
PURPOSE: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation. MATERIALS AND METHODS: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. RESULTS: The serum sCD93 levels (ng/mL) in patients with exacerbated AR (mean±standard deviation, 153...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28314658/management-of-chronic-inducible-urticaria-according-to-the-guidelines-a-prospective-controlled-study
#19
Emek Kocatürk, Pelin Kuteyla Can, Pırıl Etikan Akbas, Mehmet Copur, Ece Nur Degirmentepe, Kübra Kızıltac, Ralfi Singer
BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients...
March 1, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28303277/basophil-fc%C3%AE%C2%B5ri-expression-in-chronic-spontaneous-urticaria-a-potential-immunological-predictor-of-response-to-omalizumab-therapy
#20
Gustavo Deza, Marta Bertolín-Colilla, Ramon M Pujol, Laia Curto-Barredo, Dulce Soto, Maribel García, Pilar Hernández, Ramon Gimeno, Ana M Giménez-Arnau
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment...
March 17, 2017: Acta Dermato-venereologica
keyword
keyword
15437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"